TITLE

Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction

PUB. DATE
September 2006
SOURCE
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on the method adopted to treat patients with acute ST-segment elevation myocardial infarction. The objective was to find out the effect of the drug fondaparinux in reducing reinfarction or death in patients. Randomized placebo-controlled trial was carried out on 12,092 patients. It was found that fondaparinux reduced death or reinfarction better than the usual care without increasing bleeding in patients with acute ST-segment elevation myocardial infarction.
ACCESSION #
22493464

 

Related Articles

  • A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials. Simes, John; Voysey, Merryn; O'Connell, Rachel; Glasziou, Paul; Best, James D.; Scott, Russell; Pardy, Christopher; Byth, Karen; Sullivan, David R.; Ehnholm, Christian; Keech, Anthony // PLoS ONE;2010, Vol. 5 Issue 1, p1 

    Background: When rates of uptake of other drugs differ between treatment arms in long-term trials, the true benefit or harm of the treatment may be underestimated. Methods to allow for such contamination have often been limited by failing to preserve the randomization comparisons. In the...

  • Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: Effect of noncompliance. Cook, Nancy; Cole, Stephen; Buring, Julie // European Journal of Epidemiology;Jun2012, Vol. 27 Issue 6, p431 

    Randomized evidence for aspirin in the primary prevention of cardiovascular disease (CVD) among women is limited and suggests at most a modest effect for total CVD. Lack of compliance, however, can null-bias estimated effects. We used marginal structural models (MSMs) to estimate the etiologic...

  • Review: Routine invasive management after unstable angina or non--ST-segment elevation MI reduces risk for death or MI.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p69 

    This article presents information on a clinical study according to which routine invasive management after unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) reduces risk for death or MI. The study explored whether in patients with unstable angina or NSTEMI, initial...

  • Amlodipine plus atorvastatin demonstrates potentially synergistic cardioprotective effects in ASCOT--LLA. Sever, P.; Dahlöf, B.; Poulter, N. // Formulary;Jan2007, Vol. 42 Issue 1, p39 

    The article presents a study on the effects of synergistic cardioprotective interaction between amlodipine and atorvastatin in patients from Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). The study suggests that patients receiving amlodipine-based regimens experienced...

  • Adjunctive treatment with eplerenone reduced 30 day all cause mortality in acute myocardial infarction. Pitt, B.; White, H.; Nicolau, J. // Evidence Based Medicine;Feb2006, Vol. 11 Issue 1, p14 

    The article reports on a study to determine whether adjunctive treatment with eplerenone can decrease morbidity and mortality better than placebo in patients with acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and heart failure. A randomized placebo...

  • Is there Evidence to Support the Use of Direct Factor Xa Inhibitors in Coronary Artery Disease? Doggrell, Sheila Anne // Reviews on Recent Clinical Trials;May2011, Vol. 6 Issue 2, p147 

    As coronary artery disease (CAD) remains a leading cause of death in the world, the development of anticoagulants to prevent CAD progressing to myocardial infarction and death is a high priority. A number of direct Factor Xa (FXa) inhibitors are being developed for use in CAD. Despite being...

  • Effects of Selenium Supplementation on Cardiovascular Disease Incidence and Mortality: Secondary Analyses in a Randomized Clinical Trial. Stranges, Saverio; Marshall, James R.; Trevisan, Maurizio; Natarajan, Raj; Donahue, Richard P.; Combs, Gerald F.; Farinaro, Eduardo; Clark, Larry C.; Reid, Mary E. // American Journal of Epidemiology;Apr2006, Vol. 163 Issue 8, p694 

    Despite the documented antioxidant and chemopreventive properties of selenium, studies of selenium intake and supplementation and cardiovascular disease have yielded inconsistent findings. The authors examined the effect of selenium supplementation (200 μg daily) on cardiovascular disease...

  • Adjunctive streptokinase offers no benefit to PTCA for acute MI.  // Geriatrics;Jun1993, Vol. 48 Issue 6, p75 

    The article reports that patients who undergo percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (MI) derive no extra benefit from the routine adjunctive use of IV streptokinase, The finding was reported by the authors of a small, prospective,...

  • Mixed Results for Bone Marrow-Derived Cell Therapy for Ischemic Heart Disease. Marbân, Eduardo; Malliaras, Konstantinos // JAMA: Journal of the American Medical Association;12/12/2012, Vol. 308 Issue 22, p2405 

    The authors discuss the effect of bone marrow-derived cell therapy on safety and substitute end points in the patients after myocardial infarction (MI). They discuss two early phase studies including the Timing In Myocardial infarction Evaluation (TIME) trial and the POSEIDON trial. 120 patients...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics